PF-06801591 in non-muscle invasive bladder cancer: a Phase 3 trial on PharmaTerminal's board
Published 10/15/2026 · By Curebiology
PharmaTerminal's active-trials board this week includes a Phase 3 study of PF-06801591 in non-muscle invasive bladder cancer, recorded on ClinicalTrials.gov as NCT04165317. The study is listed as active with an enrollment of 1,068 and an estimated completion date in late 2026, making it one of the larger and nearer-term entries on the board. It sits at position 8 of the 15 trials the terminal is tracking, a board ordered by ClinicalTrials.gov last-update date.
What is being studied
The intervention recorded on the registry is PF-06801591, studied in non-muscle invasive bladder cancer. The record describes the study as Phase 3, its status field reads ACTIVE, and the enrollment figure entered is 1,068 — the largest among the top-ranked entries on this week's board. The sponsor field is recorded as Unknown, so the entry as presented does not name a sponsor.
Stage and recorded endpoint
The primary endpoint is recorded as: Cohort A: Event Free Survival (EFS) as Assessed by the Investigator: Arm A Versus Arm C. The registry lists an estimated completion date of 2026-12-02. These are registry values quoted as recorded, including the cohort and arm comparison named in the endpoint, which pairs two study arms as the record sets them out; the post does not reinterpret them into outcomes and reports no results.
Where to track this
PharmaTerminal carries this record at https://pharmaterminal.aeah.ai/#/dashboard, within the Active Clinical Trials (dashboard) section. That section is where the terminal presents live Phase 2 and Phase 3 trials, its pipeline tracker and approvals, so readers can follow this study's status and endpoint next to the other trials ranked around it on the dashboard at https://pharmaterminal.aeah.ai/#/dashboard.
Source
Upstream record: ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT04165317. The same record is presented in PharmaTerminal at https://pharmaterminal.aeah.ai/#/dashboard.
This is a summary of public registry and aggregated data and is not medical or investment advice.